Bolt Biotherapeutics Inc
(NAS:BOLT)
$
0.6876
-0.0026 (-0.38%)
Market Cap: 26.31 Mil
Enterprise Value: -28.50 Mil
PE Ratio: 0
PB Ratio: 0.31
GF Score: 40/100 - Q1 2024 Bolt Biotherapeutics Inc Earnings Call TranscriptMay 14, 2024$1.32 (-0.75%)Earnings
- Bolt Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Bolt Biotherapeutics Inc at Cowen Health Care Conference TranscriptMar 07, 2023
- Bolt Biotherapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 16, 2023
- Bolt Biotherapeutics Inc at Guggenheim Healthcare Talks Oncology Day TranscriptFeb 08, 2023
- Bolt Biotherapeutics Inc at Stifel Healthcare Conference TranscriptNov 16, 2022
- Bolt Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Bolt Biotherapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 14, 2022
- Bolt Biotherapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 09, 2022
- Bolt Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Bolt Biotherapeutics Inc CMC Considerations For In-Human Studies with Drs. Edith Perez And Nathan Ihle TranscriptSep 23, 2020
Bolt Biotherapeutics Inc at Guggenheim Healthcare Talks Oncology Day Transcript
Feb 08, 2023 / 08:55PM GMT
Release Date Price:
$1.45
(-3.33%)
Michael Schmidt
Guggenheim Partners - Analyst
Hello again. It's Michael Schmidt from the biotech team at Guggenheim. The next presenting company is Bolt Biotherapeutics. With us today, we have Willie Quinn, CFO; as well as Edith Perez, Chief Medical Officer. Welcome, guys.
Willie Quinn
Bolt Therapeutics, Inc. - CFO
Thank you.
Questions & Answers
Michael Schmidt
Guggenheim Partners - Analyst
All right. Why don't we dive right into Q&A? Perhaps for Edith. So ISACs has been a somewhat challenging category for some companies. But on the other hand, there have been a number of partnerships in the last few years in the industry, which suggests there is strategic interest in this technology. Maybe talk about your platform technology and how it's differentiated from others out there.
Edith Perez
Bolt Therapeutics, Inc. - Chief Medical Officer
Yeah, as you said, Michael, there is interest in the technology because one of the reasons for this is that it makes
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)